News | April 27, 2010

Study Shows Link Between Atrial Fibrillation, Dementia

April 27, 2010 – New findings confirm atrial fibrillation (AF) is independently associated with the risk of all forms of dementia, including Alzheimer’s and other senile and vascular dementia types. According to a study published in the April edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, the presence of AF indicated higher mortality rates in all dementia subtypes. However, mortality risk was most prominent in the youngest population studied.

The study evaluated 37,025 patients from the Intermountain Heart Collaborative Study database between the ages of 60 and 90 years over a five-year period. The study population included all patients who were seen by cardiologists for the development of atrial fibrillation and different types of dementia including vascular, senile, Alzheimer’s and other nonspecified types. During the study, a total of 10,161 patients (27 percent) developed AF and 1,535 (4.1 percent) developed dementia. Researchers also assessed the impact of AF on mortality risk in those patients diagnosed with dementia.

Study findings revealed AF is independently associated with all dementia types and, across all dementia states, cognitive decline occurred earlier in patients with AF versus no AF. Among the 764 patients who developed both AF and dementia, AF developed first, or in some cases simultaneously with dementia diagnosis. Most notably, the greatest risk of dementia was seen in the youngest AF patient group (less than 70 years old). Furthermore, the greatest increased risk of mortality was also observed in the youngest patient group.

“While age remains the strongest risk factor for dementia, our study shows the highest risk of Alzheimer’s and other dementia types was most prominent in the youngest AF patient group,” said lead author T. Jared Bunch, M.D., heart rhythm specialist, Intermountain Medical Center, Murray, Utah. “This finding is significant in establishing the association between dementia and AF and could potentially help clinicians monitor patients more closely for signs of dementia and mortality risks.”

With more than 2 million people in the United States diagnosed with atrial fibrillation, this study is an important step toward improving prevention and overall patient care. Further research may establish treatment methods for AF patients living with dementia and help reduce the mortality risk.

For more information: www.heartrhythmjournal.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now